Company Insights

DARE customer relationships

Explore interactive graphBrowse insights index

DARE customers relationship map

Daré Bioscience (DARE): Partner map and what it means for revenue and risk

Daré Bioscience is a clinical-stage women's health biopharma that monetizes through a mix of licensing deals, milestone/royalty streams, grant and contract funding, and product sales where it retains commercial rights. The company’s economics hinge on a small number of high-impact partner arrangements (licensing to large pharma and grant/contract awards) and intermittent direct sales opportunities; investors should value Daré as a rights-holder and asset developer whose near-term cash flow is driven by partner payments and external grants. For a concise dashboard of Daré’s counterparties, visit https://nullexposure.com/.

How Daré actually operates and earns money

Daré advances clinical candidates in women’s health and then executes one of three commercialization paths: out-license to a larger pharmaceutical company for development and commercialization (yielding milestones and royalties), retain rights and commercialize directly, or leverage third‑party funding such as government/ foundation contracts to de-risk development. The company has also monetized intellectual property through royalty purchase transactions (XOMA) that converted future royalty streams into upfront cash. Financials show low revenue today and negative operating margins, so partner payments, milestone timing, and grant inflows are critical to near-term liquidity and value realization.

Business model signals and operating constraints

  • Contracting posture — licensing is central. Company disclosures cite an exclusive worldwide license with Organon for XACIATO and milestone/royalty structures; licensing is a primary commercial route for Daré.
  • Geographic scale — global reach via partners. Organon’s rights are described as worldwide, indicating Daré pursues global commercialization through partners rather than building full global commercial infrastructure itself.
  • Role diversity — Daré is both licensor and seller. Filings document that Daré acts as a licensor for partnered products and as a seller/provider for certain formulations and interim supply—this dual posture diversifies but also complicates revenue recognition.
  • Maturity and stage — asset-stage company with active partnered commercialization. Organon commenced U.S. marketing of XACIATO in late 2023, while other assets remain in pivotal trials or earlier stages.
  • Cash and concentration risk — partner milestones and grants are critical. Given small TTM revenue and negative margins, Daré’s operating runway and upside rely on milestone payments, royalties, grant/contract receipts, and the success of high-value clinical programs.

If you want an investor-ready map of counterparties and implications, see https://nullexposure.com/ for more.

Relationship breakdown — every reported counterpart and what they do for Daré

Below I list each reported relationship entry from the public record with a concise 1–2 sentence summary and the underlying source.

  • Rosy Wellness — Daré has a partnership referenced in the company’s Q3 2025 earnings call regarding the “DARE to PLAY” program. The mention in the 2025Q3 earnings call confirms a strategic collaboration for that branded initiative (source: 2025Q3 earnings call transcript).

  • BAYN (Bayer) — A GlobeNewswire release (Sep 24, 2025) lists Ovaprene as an investigational, hormone‑free monthly intravaginal contraceptive whose U.S. commercial rights were under license to Bayer, tying Daré’s Ovaprene economics to Bayer’s commercialization decisions (source: GlobeNewswire, Sep 24, 2025).

  • Advanced Research Projects Agency for Health (ARPA‑H) — News coverage (Bitget, May 2026) reports that a planned Phase 2 clinical program is supported by a $10 million ARPA‑H contract, with $6.5 million received to date, indicating material government contract funding for DARE‑HPV research (source: Bitget news, May 2, 2026).

  • Bayer (duplicate GlobeNewswire entry) — The same GlobeNewswire item reiterates that Ovaprene’s U.S. rights were licensed to Bayer; the press release frames the asset within Daré’s clinical portfolio (source: GlobeNewswire, Sep 24, 2025).

  • Gates Foundation (GlobeNewswire 2025) — Daré announced an agreement to receive up to approximately $499,000 from the Gates Foundation to provide mentorship and project management support for third‑party preeclampsia research, representing philanthropic funding and program management services (source: GlobeNewswire, Sep 24, 2025).

  • OGN (Organon, GlobeNewswire) — GlobeNewswire (Sep 24, 2025) highlights that XACIATO, Daré’s FDA‑approved vaginal gel, is governed by a global license agreement with Organon, under which Daré retains milestone/royalty economics rather than direct commercialization (source: GlobeNewswire, Sep 24, 2025).

  • Organon (GlobeNewswire duplicate) — The same GlobeNewswire release explicitly names Organon as the licensee for XACIATO and situates that product as Daré’s first FDA‑approved asset to emerge from its portfolio (source: GlobeNewswire, Sep 24, 2025).

  • Gates Foundation (GlobeNewswire Nov 3, 2025) — A separate GlobeNewswire release (Nov 3, 2025) documents a contract under which Daré can receive up to ~$300,000 to conduct a strategic landscape review for contraceptive development capabilities, underlining continued Gates support for Daré’s non‑clinical advisory work (source: GlobeNewswire, Nov 3, 2025).

  • Organon (QuiverQuant) — Coverage of Daré’s positive interim Phase 3 Ovaprene data notes Organon’s existing license for XACIATO and references Organon as an established commercialization partner for other assets (source: QuiverQuant news, 2025).

  • Bayer (Investing.com, May 2026) — Investing.com reported that Bayer terminated its license agreement and returned rights to Ovaprene effective February 2026, a material change that restores commercial control of Ovaprene to Daré (source: Investing.com, May 2, 2026).

  • Bayer HealthCare (Investing.com) — A filing summarized by Investing.com notes Daré will regain full rights to Ovaprene from Bayer HealthCare, shifting the asset from partner‑led commercialization back to Daré (source: Investing.com, FY2026 sec filings).

  • BAYRY (Investing.com duplicate) — An additional Investing.com entry repeats that Daré regains Ovaprene rights from Bayer HealthCare, confirming the formal return of rights in FY2026 commentary (source: Investing.com, FY2026).

  • BAYRY (QuiverQuant FY2025) — QuiverQuant reported that Bayer previously had the right to obtain exclusive U.S. commercialization rights for Ovaprene upon completion of pivotal trials and a potential $20 million payment to Daré, highlighting the previously contingent milestone structure (source: QuiverQuant, FY2025).

  • OGN (QuiverQuant FY2025) — QuiverQuant also reiterates that XACIATO is licensed globally to Organon, confirming the structure under which Daré receives downstream economics (source: QuiverQuant, FY2025).

  • BAYRY (QuiverQuant duplicate) — A second QuiverQuant entry restates Bayer’s conditional commercialization rights tied to payments, reinforcing the historic commercial option framework (source: QuiverQuant, FY2025).

  • Bayer HealthCare LLC (SAHM Capital, Dec 1, 2025) — SAHM Capital reports that Bayer HealthCare LLC elected to terminate the Ovaprene license and return rights to Daré as part of strategic reprioritization, an event that materially increases Daré’s control over a pivotal program (source: SAHM Capital press release, Dec 1, 2025).

  • BAYRY (SAHM duplicate) — A duplicate SAHM Capital entry confirms the rights return statement and the company’s public positioning of Ovaprene as an asset for value maximization under Daré stewardship (source: SAHM Capital, Dec 1, 2025).

  • BAYRY (Yahoo Finance FY2024) — A 2024 Yahoo Finance item previously described Ovaprene’s U.S. commercial rights being under license with Bayer, documenting the historical licensing relationship before the rights reversion (source: Yahoo Finance, FY2024).

  • Organon (Yahoo Finance FY2024) — Yahoo Finance also documented that XACIATO is under a global license with Organon, corroborating Organon’s role in commercializing Daré’s FDA‑approved product (source: Yahoo Finance, FY2024).

  • OGN (Yahoo Finance duplicate FY2024) — A duplicate Yahoo article again notes the Organon license for XACIATO, underscoring that Organon commercialization has been public since FY2024 (source: Yahoo Finance, FY2024).

  • Bayer (GlobeNewswire Aug 14, 2025) — Daré’s Q2 2025 financial results release (Aug 14, 2025) lists Ovaprene as licensed to Bayer for U.S. commercial rights, consistent with public filings through mid‑2025 (source: GlobeNewswire, Aug 14, 2025).

  • BAYRY (GlobeNewswire duplicate Aug 14, 2025) — The Q2 2025 release is reiterated in a duplicate entry documenting the same licensing language for Ovaprene with Bayer (source: GlobeNewswire, Aug 14, 2025).

  • OGN (GlobeNewswire Q2 2025 duplicate) — The Q2 release likewise reiterates that XACIATO is under a global license agreement with Organon (source: GlobeNewswire, Aug 14, 2025).

  • ARPA‑H (QuiverQuant May 2026) — QuiverQuant reports that the Phase 2 DARE‑HPV program benefits from a $10 million ARPA‑H contract with $6.5 million received, signaling sizeable non‑dilutive government funding for this clinical program (source: QuiverQuant, May 2, 2026).

  • ARPA‑H (QuiverQuant duplicate) — A second QuiverQuant entry restates the ARPA‑H contract funding and receipt amount, reinforcing the same funding profile for FY2026 (source: QuiverQuant, May 2, 2026).

  • Organon (Yahoo Finance host Aug 6, 2025) — An investor notice hosted on Yahoo Finance reiterates that XACIATO is licensed globally to Organon, giving investors a consolidated public record of that arrangement (source: Yahoo Finance investor release, Aug 6, 2025).

  • Bayer / Organon (Yahoo Finance duplicates) — Additional Yahoo Finance entries duplicate earlier notes that Ovaprene was licensed to Bayer and XACIATO licensed to Organon in public disclosures and investor presentations spanning FY2024–FY2025 (source: Yahoo Finance, FY2024–FY2025).

What investors should take away

  • Licensing-driven value: Daré’s most significant commercial relationships have been structured as licensing deals (Organon for XACIATO; historically Bayer for Ovaprene), which creates milestone and royalty upside but also transfers commercialization execution risk to partners.
  • Reversion of Ovaprene rights is material: Bayer’s termination and return of Ovaprene rights (reported across multiple filings and press outlets in late 2025–early 2026) converts a formerly contingent partner milestone into an asset Daré directly controls, changing both execution risk and potential capital needs.
  • Non‑dilutive funding is meaningful: ARPA‑H contract receipts and Gates Foundation grants introduce non‑equity funding that supports development and reduces dilution risk while focusing resources on prioritized programs.
  • Concentration and timing risk: With low absolute revenues and negative margins, Daré’s near‑term financial trajectory is sensitive to the timing of milestone receipts, grant payments, and clinical results.

For an investor-ready counterparty map and model sensitivities, visit https://nullexposure.com/.

Conclusion: Daré’s value will be realized through successful de‑risking of clinical programs, monetization events with corporate partners, and continued strategic grant/contract support; monitor Ovaprene commercialization strategy, ARPA‑H funding milestones, and any new licensing or royalty monetization steps closely.

Join our Discord